Autism

A Groundbreaking Forum at HIMSS25 Focused on Behavioral HealthA Groundbreaking Forum at HIMSS25 Focused on Behavioral Health

A Groundbreaking Forum at HIMSS25 Focused on Behavioral Health

LAS VEGAS, Jan. 15, 2025 /PRNewswire/ -- Informa Connect announces a landmark collaboration with Behavioral Health Tech to present the…

4 months ago
Stride Autism Centers Named a Winner of the 2025 Top Workplaces Award in the Great PlainsStride Autism Centers Named a Winner of the 2025 Top Workplaces Award in the Great Plains

Stride Autism Centers Named a Winner of the 2025 Top Workplaces Award in the Great Plains

Stride Autism Centers Named a Winner of the 2025 Top Workplaces Award in the Great Plains Stride Autism Centers, a…

4 months ago
Behavioral Innovations Celebrates 25 Years of Transforming Lives Through Compassionate ABA TherapyBehavioral Innovations Celebrates 25 Years of Transforming Lives Through Compassionate ABA Therapy

Behavioral Innovations Celebrates 25 Years of Transforming Lives Through Compassionate ABA Therapy

Honoring a Quarter Century of Dedicated Support for Children with Autism and Their Families DALLAS, TEXAS / ACCESSWIRE / January…

4 months ago
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other ConditionsPaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions

PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions

BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing…

4 months ago
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes EnrollmentClinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment

Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment

ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology…

4 months ago
RethinkFirst Appoints Ben Semmes as Chief Executive OfficerRethinkFirst Appoints Ben Semmes as Chief Executive Officer

RethinkFirst Appoints Ben Semmes as Chief Executive Officer

Transformational executive to lead company through the next phase of growth and innovation NEW YORK, Jan. 8, 2025 /PRNewswire/ --…

4 months ago
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination TreatmentClearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

4 months ago
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…

4 months ago
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum DisorderSciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…

4 months ago
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct ImportationSciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors…

5 months ago